TITLE

Epidermal growth factor receptor-binding growth factors in the urine of patients with cancers of the digestive tract

AUTHOR(S)
Chuang, Lea-Yea; You, Huei-Lin; Tsai, Jung-Fa
PUB. DATE
August 2000
SOURCE
Journal of Gastroenterology;2000, Vol. 35 Issue 8, p598
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Abstract: We aimed to assess the diagnostic application of urinary epidermal growth factor receptor (EGFR) binding growth factors in cancers of the digestive tract. By radioreceptor assay and radioimmunoassay, we determined these growth factors in 115 patients with various cancers of the digestive tract, 30 patients with benign disease, and 40 healthy controls. The receiver operating characteristic (ROC) curve and likelihood ratio were employed to determine the best diagnostic efficiency. Urinary EGFR-binding growth factors in each cancer group were significantly higher than those in the non-cancer groups. Multivariate analysis indicated that the growth factors, determined by both the radioreceptor assay (odds ratio, 1.184; 95% confidence interval, 1.077-1.302; P = 0.001) and radioimmunoassay (odds ratio, 1.055; 95% confidence interval, 1.002-1.111; P = 0.039), were associated, in a dose-related fashion, with the presence of cancers. By ROC curve analysis, the optimal cutoff values for EGFR-binding growth factors were 25.5 micro g/g creatinine (radioreceptor assay) and 33.6 micro g/g creatinine (radioimmunoassay). The resulting sensitivity, specificity, diagnostic accuracy, and positive and negative likelihood ratios were 84.4%, 87.5%, 85.2%, 6.75 and 0.18 (for radioreceptor assay) and 86.1%, 67.5%, 81.3%, 2.64 and 0.21 (for radioimmunoassay), respectively. Except for pancreatic cancer the growth factors showed moderate diagnostic efficiency for the other digestive tract cancers. In conclusion, urinary EGFR-binding growth factors were increased in cancers of the digestive tract. They may be used as diagnostic tumor markers.
ACCESSION #
4689898

 

Related Articles

  • Indomethacin Interferes with EGF-Induced Activation of Ornithine Decarboxylase in Gastric Cancer Cells. Ishikawa, T.; Ichikawa, Y.; Tarnawski, A.; Fujiwara, Y.; Fukuda, T.; Arakawa, T.; Mitsuhashi, M.; Shimada, H. // Digestion;1998, Vol. 59 Issue 1, p47 

    Background/Aims: Epidermal growth factor (EGF) has a wide variety of biological activities in the protection of gastric mucosa against acute injury and the healing of gastric ulcer. However, the molecular basis of the EGF action remains unknown. EGF-induced activation of ornithine decarboxylase...

  • MOLECULAR EXPRESSION OF BREAST TUMOUR MARKERS IN THE MNU MODEL FOLLOWING BFGF AND PF4 INTERVENTION. Norasikin, M. N.; Hasnan, J. // Malaysian Journal of Medical Sciences;Jan2007 Supplement, Vol. 14, p93 

    Introduction: Angiogenesis plays an important role in breast cancer development. Rapid tumour growth is dependent on angiogenesis to support the metabolic need of the fast-growing transformed tumour cells and the growth of the tumour beyond a certain size requires angiogenesis. While many...

  • Targeting ERBB Receptors to Inhibit Metastasis: Old Hopes and New Certainties. Angelucci, Adriano // Current Cancer Drug Targets;Feb2009, Vol. 9 Issue 1, p1 

    The very early intuition of Paget about the molecular feature of metastasis has come in the field of therapeutic opportunities only in the last few years with the development of targeted therapy. However, to date the diagnosis of metastases is associated in the majority of cases with the loss of...

  • Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grace ductal carcinomas with myoepithelial differentiation. Shien, T.; Tashiro, T.; Omatsu, M.; Masuda, T.; Furuta, K.; Sato, N.; Akashi-Tanaka, S.; Uehara, M.; Iwamoto, E.; Kinoshita, T.; Fukutomi, T.; Tsuda, H.; Hasegawa, T. // Journal of Clinical Pathology;Dec2005, Vol. 58 Issue 12, p1299 

    Aims: To evaluate the expression of common biological markers and the epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation (DCMDs). Materials/methods: Thirty DCMDs were clinicopathologically and immunohistochemically analysed and...

  • Study of HER1, HER2 Over Expression in Locally Advanced Gastric Cancer and Their Correlation with Overall Survival. Janbabaee, Ghasem; Naghshvar, Farshad; Farazmandfar, Tooraj; Salehi, Mostafa; Rashidi, Masoomeh // Journal of Mazandaran University of Medical Sciences (JMUMS);Sep2012, Vol. 22 Issue 92, p1 

    Background and purpose: Mortality rate from gastric cancer is growing in the world. Nowadays a very precise relationship exists between the development of cancer and changes in EGF receptor expression levels in many cancers. Probably, one of the best known of these changes is over expression of...

  • Comparison of Global versus Epidermal Growth Factor Receptor Pathway Profiling for Prediction of Lapatinib Sensitivity in Bladder Cancer. Havaleshko, Dmytro M.; Smith, Steven Christopher; HyungJun Cho; Sooyoung Cheon; Owens, Charles R.; Lee, Jae K.; Liotta, Lance A.; Espina, Virginia; Wulfkuhle, Julia D.; Petricoin, Emanuel F.; Theodorescu, Dan // Neoplasia;Nov2009, Vol. 11 Issue 11, p1185 

    Chemotherapy for metastatic bladder cancer is rarely curative. The recently developed small molecule, lapatinib, a dual epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor-2 receptor tyrosine kinase inhibitor, might improve this situation. Recent findings suggest that...

  • Optimal Adjuvant Therapy for Non-Small Cell Lung Cancer--How to Handle Stage I Disease. Wakelee, Heather; Dubey, Sarita; Gandara, David // Oncologist;Mar2007, Vol. 12 Issue 3, p331 

    The standard of care for resected stage II-IIIA non-small cell lung cancer (NSCLC) now includes adjuvant chemotherapy based on the results of three phase III studies using cisplatin-based regimens--the International Adjuvant Lung Trial, the National Cancer Institute of Canada JBR.10 trial, and...

  • Determination of EGFR mutations in single cells microdissected from enriched lung tumor cells in peripheral blood. Ran, Ran; Li, Longyun; Wang, Mengzhao; Wang, Shulan; Zheng, Zhi; Lin, Peter // Analytical & Bioanalytical Chemistry;Sep2013, Vol. 405 Issue 23, p7377 

    A minimally invasive and repeatable approach for real-time epidermal growth factor receptor ( EGFR) mutation surveillance would be highly beneficial for individualized therapy of late stage lung cancer patients whose surgical specimens are often not available. We aim to develop a viable method...

  • Fluorodeoxyglucose positron emission tomography and chemotherapy-related tumor marker expression in non-small cell lung cancer. Duan, Xiao-Yi; Wen Wang; Wang, Jian-Sheng; Jin Shang; Gao, Jun-Gang; Guo, You-Min // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background The chemotherapy resistance of non-small cell lung cancer (NSCLC) remains a clinic challenge and is closely associated with several biomarkers including epidermal growth factor receptor (EGFR) ( Drugs 72(Suppl 1):28-36, 012.), p53 ( Med Sci Monit 11(6):HY11- HY20, 2005.) and excision...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics